Glutaminase C-IN-1
Based on 11 publication(s) in Google Scholar
Glutaminase C-IN-1 (Compound 968) is an allosteric inhibitor of Glutaminase C that inhibits cancer cell growth without affecting their normal cellular counterparts.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 311795-38-7
- Formula: C27H27BrN2O
- Molecular Weight:475.42
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Glutaminase C-IN-1
More- J Hepatol. 2020 May;72(5):909-923. [Abstract]
- Cell Metab. 2023 Jan 3;35(1):200-211.e9. [Abstract]
- Nat Cancer. 2022 Aug;3(8):945-960. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(21):e13341. [Abstract]
- Cell Death Discov. 2021 Aug 5;7(1):204. [Abstract]
- Dev Cell. 2025 Jul 21;60(14):1958-1973.e9. [Abstract]
- JCI Insight. 2025 Jul 22;10(14):e189858. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178739. [Abstract]
- Int Immunopharmacol. 2026 Mar 1:172:116106. [Abstract]
- Front Biosci (Landmark Ed). 2022 Aug 15;27(8):243. [Abstract]
- SSRN. 2025 Nov 8.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Biological Activity
Glutaminase C[2]
Glutaminase C-IN-1 (Compound 968) (10 μM; 14 d) inhibits cellular transformation in NIH 3T3 cells[1].
Glutaminase C-IN-1 (10 μM; 6 d) blocks the signaling activity of a specific target of Dbl[1].
Glutaminase C-IN-1 blocks the transforming activity of human breast cancer cells[1].
Glutaminase C-IN-1 (10 μM) blocks glutaminolysis in transformed cells[2].
Glutaminase C-IN-1 preferentially binds to the monomeric state of Glutaminase C[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB231 cells, SKBR3 cells, and NIH 3T3 cells
-
Concentration:10 μM
-
Incubation Time:5 h
-
Result:Inhibited cell growth.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice with P493 B lymphoma cells[1]
-
Dosage:200 μg/mouse
-
Administration:Intraperitoneal injection, daily for 12 days
-
Result:Caused a ~50% reduction in the size of the tumors.
Chemical Information
-
CAS No. 311795-38-7
-
Appearance Solid
-
Molecular Weight 475.42
-
Formula C27H27BrN2O
-
Color White to off-white
-
SMILES
O=C1C(C(C2=CC=C(N(C)C)C(Br)=C2)NC3=C4C5=CC=CC=C5C=C3)=C4CC(C)(C)C1
-
Synonyms
Compound 968
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
J Hepatol
2020 May;72(5):909-923. PMID: 31899205
Glutaminase C-IN-1 purchased from MedChemExpress. Usage Cited in: J Hepatol. 2020 May;72(5):909-923. [Abstract]
Proliferation of HCC-LM3 cells treated with Ctrl, 5 μM 968 alone, 4 μM Sor alone, and combined 5 μM 968 and 4 μM Sor (968+Sor).
-
Cell Metab
Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. [Abstract]2023 Jan 3;35(1):200-211.e9. PMID: 36309010 -
Nat Cancer
Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth. [Abstract]2022 Aug;3(8):945-960. PMID: 35982178 -
Adv Sci (Weinh)
Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]2026 Apr;13(21):e13341. PMID: 41684301 -
Cell Death Discov
Compound 968 reverses adriamycin resistance in breast cancer MCF-7ADR cells via inhibiting P-glycoprotein function independently of glutaminase. [Abstract]2021 Aug 5;7(1):204. PMID: 34354052 -
Dev Cell
Glutamine binds HSC70 to transduce signals inhibiting IFN-β-mediated immunogenic cell death. [Abstract]2025 Jul 21;60(14):1958-1973.e9. PMID: 40086433 -
JCI Insight
Metabolic pathways within cTfh subsets and glucose-dependent activation of cTfh17 in SLE and healthy individuals. [Abstract]2025 Jul 22;10(14):e189858. PMID: 40693461 -
Eur J Pharmacol
Obesity-associated metabolic dysregulation aggravates myocardial ischemia-reperfusion injury through Gls2-mediated ferroptosis. [Abstract]2026 Mar 28:1019:178739. PMID: 41819522 -
Int Immunopharmacol
PIK3CG deficiency promotes metabolic reprogramming in pancreatic Cancer by suppressing GLS2-driven glutamine metabolism. [Abstract]2026 Mar 1:172:116106. PMID: 41539001 -
Front Biosci (Landmark Ed)
Dysfunction of Cytotoxic T Lymphocyte Induced by Hepatoma Cells through the Gln-GLS2-Endoplasmic Reticulum Stress Pathway. [Abstract]2022 Aug 15;27(8):243. PMID: 36042180 -
Solvent & Solubility
DMSO : 25 mg/mL (52.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.26 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang JB, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010 Sep 14;18(3):207-19. [Content Brief]
[2]. Stalnecker CA, et al. Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):394-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1034 mL | 10.5170 mL | 21.0340 mL | 52.5851 mL |
| 5 mM | 0.4207 mL | 2.1034 mL | 4.2068 mL | 10.5170 mL | |
| 10 mM | 0.2103 mL | 1.0517 mL | 2.1034 mL | 5.2585 mL | |
| 15 mM | 0.1402 mL | 0.7011 mL | 1.4023 mL | 3.5057 mL | |
| 20 mM | 0.1052 mL | 0.5259 mL | 1.0517 mL | 2.6293 mL | |
| 25 mM | 0.0841 mL | 0.4207 mL | 0.8414 mL | 2.1034 mL | |
| 30 mM | 0.0701 mL | 0.3506 mL | 0.7011 mL | 1.7528 mL | |
| 40 mM | 0.0526 mL | 0.2629 mL | 0.5259 mL | 1.3146 mL | |
| 50 mM | 0.0421 mL | 0.2103 mL | 0.4207 mL | 1.0517 mL |
Glutaminase C-IN-1 Related Classifications
HY-12682 Related Classifications
Powered by Bioz